{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-22-000027","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.052708+00:00","generated_at":"2026-06-25T20:34:18.130560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exagen Q1 revenue $10.4M, net loss widens to $10.3M; raises FY 2022 guidance","bullets":["Q1 testing revenue $10.4M (flat YoY); total revenue $10.4M vs $10.6M in Q1 2021.","Net loss $10.3M ($0.84 loss per share) vs $6.2M loss a year ago; gross margin fell to 44% from 55.5%.","AVISE CTD test volume 30,903 (+6.5% YoY); record 2,175 ordering healthcare providers and 761 adopters.","FY 2022 revenue guidance raised to $53-55M from $51-53M; cash $89.8M at quarter end.","AMA issued PLA code for AVISE Lupus; Centene/WellCare in-network effective June 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-22-000027","json":"https://secwatch.observer/filing/0001274737-22-000027.json","markdown":"https://secwatch.observer/filing/0001274737-22-000027.md","text":"https://secwatch.observer/filing/0001274737-22-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/0001274737-22-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000027/exdx-20220511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T20:34:18.130560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}